From Extracting Pituitary Glands of Discarded Cows and Pigs to World Leader in Infertility Treatment [Corporate Research Institute]
"People First" at Ferring Pharmaceuticals
Helping Everyone Build Families, Specializing in Infertility and Reproductive Medicine
Investing 16% of Sales in R&D... Leading Innovation in Specialized Therapies
In the 1950s, Malm?, Sweden, was home to thriving large-scale shipyards, while nearby areas were also active in the dairy and meat processing industries. Dr. Frederik Paulsen, who needed animal organs for research in endocrinology and hormones, established the "Nordiska Hormone Laboratory" in Malm?. In this office-cum-laboratory, Dr. Paulsen devoted himself to extracting adrenocorticotropic hormone (ACTH) from the pituitary glands of discarded cows and pigs. Eventually, in 1956, Dr. Paulsen opened his first in-house production facility, and by 1961, he succeeded in mass-producing synthetic peptide hormones. Dr. Paulsen's research is credited with pioneering a revolutionary path in endocrine therapy.
In 1954, Dr. Paulsen changed the name of his laboratory to "Ferring." "Ferring" is a Frisian (a West Germanic language) term referring to people from F?hr Island, located off the west coast of Germany. Although Dr. Paulsen was born and raised in Dageb?ll, northern Germany, his parents were from F?hr Island, and he took pride in his F?hr heritage. After being imprisoned for opposing Nazism, Dr. Paulsen moved to Switzerland upon his release, earned his medical doctorate, and then immigrated to Sweden, where he founded what is now Ferring Pharmaceuticals.
Dr. Paulsen's philosophy of valuing family became the foundation of the company. Ferring Pharmaceuticals' mission is "to help everyone build families and live better lives." Based on this philosophy, Ferring Pharmaceuticals has focused on areas such as gastroenterology, urology, and, in particular, infertility and reproductive medicine, growing into a global company. Today, the company employs 7,000 people in 50 countries, and its products are sold in over 100 countries worldwide.
With a 75-year history, Ferring Pharmaceuticals has been a leader in infertility and reproductive medicine, conducting the largest number of clinical studies in the field. The company is also actively developing new drugs and products based on scientific research. Following treatments for inflammatory bowel disease and nocturnal enuresis, the company plans to seek approval in Korea this year for a gene therapy for bladder cancer.
Unlike most Korean pharmaceutical companies, which are publicly traded, Ferring Pharmaceuticals is a privately held, family-owned company. This allows the company to focus on long-term research without being swayed by short-term stock price fluctuations. Ferring Pharmaceuticals takes pride in having continued innovation in specialized therapeutic areas through consistent investment.
Indeed, the company spares no expense in R&D investment. Ferring Pharmaceuticals has its main R&D headquarters in Copenhagen, Denmark, and operates research centers in major regions worldwide, including the United States, China, and Israel. As a private company, it does not disclose the number of employees or the scale of investment by country, but in 2024, it invested approximately 16% of its sales (2.343 billion euros, about 4 trillion won) in R&D. By comparison, Hanmi Pharmaceutical, known for having the highest R&D ratio among Korean pharmaceutical companies, spent 15% of its sales on R&D last year. Most Korean pharmaceutical companies are known to invest less than 10% of their sales in R&D.
Kim Minjung, CEO of Ferring Pharmaceuticals Korea, recently stated in a written interview with The Asia Business Daily, "Ferring Pharmaceuticals Korea plans to reliably connect the expertise and innovation of the global Ferring Group to the domestic market." Ferring Pharmaceuticals Korea
View original imageMarking its 75th anniversary, Ferring Pharmaceuticals' long-term strategy is not simply to expand its product lineup, but to change the standard of care in disease areas that have a significant impact on family formation and quality of life. Kim Minjung, CEO of Ferring Pharmaceuticals Korea, said, "In the field of infertility and reproductive medicine, we plan to strengthen solutions that cover the entire spectrum of patients seeking pregnancy. In gastroenterology, we will focus on treatment approaches aimed at preventing recurrence and managing conditions. In the fields of urology and oncology, including bladder cancer, our vision is to present new treatment paradigms through innovative technologies, including gene therapy."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kim emphasized, "Beyond short-term product performance, our goal at Ferring Pharmaceuticals Korea is to become a trusted specialist partner for both patients and healthcare professionals in each therapeutic area. We will continue to pursue sustainable growth in the Korean market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.